drugset / Trial / NCT05705700
Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, Phase II randomized biomarker-based therapeutic study in metastatic prostate cancer experiencing prostate specific antigen (PSA) only progression (without visceral, bone or lymph node progression) while on abiraterone therapy.
Timeline
- Start
- 2023-02
- Primary completion
- 2030-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dutasteride | Small molecule | 3.5 mg | Oral |
| Background | Abiraterone acetate | Small molecule | 1000 mg | Oral |